Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded. [Operator Instructions] I will now turn the ...
Breaking up isn’t so hard to do, after all. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & Johnson aims to part ways with its orthopedics unit, which will take with ...
Johnson & Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75. The pharmaceutical and medtech ...
Strengthens focus of Johnson & Johnson (JNJ) as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results